News | Women's Health | February 09, 2017

MD Anderson study finds correlation between density, cancer in other breast

dense breast tissue, contralateral breast cancer, MD Anderson study, Cancer journal

February 9, 2017 — Breast cancer patients with dense fibroglandular breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.

The study, published in the journal Cancer, is among the first to find the association between breast density (BD) and contralateral breast cancer (CBC).

According to study author Isabelle Bedrosian, M.D., a big challenge in the management of this patient population, especially as they are making surgical decisions, is trying to counsel women appropriately on their risk of developing breast cancer in the other breast.

"We know there are a number of well-established influences for developing both primary and secondary breast cancers, such as BRCA mutations, family history and the tumor's estrogen receptor status," explained Bedrosian, associate professor, breast surgical oncology. "We also know density is a risk factor for the development of primary breast cancer. However, no one has closely looked at it as a risk factor for developing contralateral disease."

The estimated 10-year risk for women with breast cancer developing CBC can be as low as 2 percent, and as high 40 percent, said Bedrosian. The dramatic range is due in large part to the variability of risk factors across the patient population, she explained.

For the retrospective, case-controlled study, the researchers identified 680 stage I, II and III breast cancer patients, all treated at MD Anderson between 1997 and 2012. BRCA patients were excluded from the study, given their known increased risk of CBC.

Women with an additional diagnosis of metachronous CBC — defined as BC in the opposite breast diagnosed more than six months after the initial diagnosis — were the "cases," and patients who had not developed CBC were the "controls." Cases and controls were matched on a 1:2 ratio based on a number of factors, including age, year of diagnosis and hormone receptor status.

"With our research, we wanted to evaluate the relationship between the mammographic breast density of the original disease and the development of metachronous breast cancer," said Carlos Barcenas, M.D., assistant professor, breast medical oncology, and the study's corresponding author.

Of the selected patients, 229 were cases and 451 were controls. The MD Anderson researchers categorized each patient's breast density by mammogram reading, assessed at the time of first diagnosis, as "nondense" or "dense," using the categorizations from the American College of Radiology.

Among the cases, 39.3 percent were classified as having nondense breast tissue and 60.7 percent as having dense breast tissue, compared to 48.3 percent and 51.7 percent, respectively, in the controls.

After adjusting for known breast cancer risk factors, the researchers found almost a two-fold increased risk of developing CBC in breast cancer survivors with dense breasts.

"Our findings have valuable implications for both newly diagnosed patients with dense breasts and for breast cancer survivors as we manage their long-term risk of a secondary diagnosis," said Barcenas. "Our future goal is to develop a risk model incorporating breast density to best assess a breast cancer survivor's risk of developing CBC."

In the long-term, the researchers hope to use this tool to counsel patients on their personal risk and their options for treatment and surveillance, if their risk is sufficiently high.

In addition to Barcenas and Bedrosian, authors on the all-MD Anderson study include: Debu Tripathy, M.D., Yu Shen, Ph.D., Banu Arun, M.D., Akshara Raghavendra, M.D., Limin Hsu, Modesto Patangan, Jr., and Arup K. Sinha, all of Breast Medical Oncology; Huong Le-Petross, M.D., and Naveen Garg, M.D., Diagnostic Radiology; and Therese Bartholomew Bevers, M.D., Clinical Cancer Prevention.

The study was supported by The University of Texas MD Anderson Cancer Center Young Breast Cancer Survivors Program.

For more information: www.canceronline.wiley.com

References

Raghavendra, A., Sinha, A.K., Le-Petross, H.T., Garg, N., et al. "Mammographic breast density is associated with the development of contralateral breast cancer," Cancer. Published online Jan. 30, 2017. DOI: 10.1002/cncr.30573


Related Content

News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Women's Health

Dec. 1, 2025 — ScreenPoint Medical has completed a commercial agreement making its Transpara breast-imaging AI portfolio ...

Time December 03, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Artificial Intelligence

Nov. 25, 2025 – Medical imaging AI company Avicenna.AI has announced a strategic partnership with Ferrum, an AI ...

Time November 25, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
Subscribe Now